Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report)’s share price was down 4.2% during mid-day trading on Monday . Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Get Climb Bio alerts:Check Out Our Latest Stock Report on Climb BioClimb Bio Stock Up 6.4%The firm has a market cap of $719.19 million, a P/E ratio of -16.10 and a beta of 0.08. On average, sell-side analysts anticipate that Climb Bio, Inc. will post -0.87 EPS for the current fiscal year. Recommended StoriesReceive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.